B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.
B cell
Immune Checkpoint Inhibitors
Tumor microenvironment - TME
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
accepted:
31
03
2024
medline:
19
4
2024
pubmed:
18
4
2024
entrez:
17
4
2024
Statut:
epublish
Résumé
Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets of patients and is now the standard of care in several solid tumor types. However, immunotherapy activity beyond conventional immune checkpoint inhibition is plateauing, and biomarkers are overall lacking to guide treatment selection. Most studies have focused on T cell engagement and response, but there is a growing evidence that B cells may be key players in the establishment of an organized immune response, notably through tertiary lymphoid structures. Mechanisms of B cell response include antibody-dependent cellular cytotoxicity and phagocytosis, promotion of CD4+ and CD8+ T cell activation, maintenance of antitumor immune memory. In several solid tumor types, higher levels of B cells, specific B cell subpopulations, or the presence of tertiary lymphoid structures have been associated with improved outcomes on immune checkpoint inhibitors. The fate of B cell subpopulations may be widely influenced by the cytokine milieu, with versatile roles for B-specific cytokines B cell activating factor and B cell attracting chemokine-1/CXCL13, and a master regulatory role for IL-10. Roles of B cell-specific immune checkpoints such as TIM-1 are emerging and could represent potential therapeutic targets. Overall, the expanding field of B cells in solid tumors of holds promise for the improvement of current immunotherapy strategies and patient selection.
Identifiants
pubmed: 38631710
pii: jitc-2023-008636
doi: 10.1136/jitc-2023-008636
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Cytokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: RF. Honoraria: Bayer, Astellas, Janssen, BMS, MSD, Ipsen, Pfizer, Merck, Astra Zeneca. MT. NoneMR-C. NoneLC-A. NoneLR. NoneNN. Honoraria: Merck, PfizerJ-MJ. NoneLB. NoneMN. NoneBE. Honoraria: Bristol:Myers Squibb, Ipsen, Oncorena, Pfizer. Consulting or Advisory Role : AVEO, Bristol:Myers Squibb, Ipsen, Oncorena, Pfizer. Research Funding : BMS France (Inst). Travel, Accommodations, Expenses : Bristol:Myers Squibb, Ipsen, MSDLC. NoneLA. Consulting or Advisory Role: Astellas Pharma (Inst), Bristol:Myers Squibb (Inst), Eisai (Inst), Ipsen (Inst), Janssen (Inst), MSD (Inst), Pfizer (Inst), Roche (Inst). Travel, Accommodations, Expenses: BMS, Ipsen, MSDNC. Scientific grants from Sanofi, BMS, Cytune Pharma, Scientist advisory board from Servier, lectures for AstraZeneca.
Références
Nat Commun. 2022 Jun 7;13(1):3148
pubmed: 35672305
J Clin Invest. 2011 Sep;121(9):3645-56
pubmed: 21821911
Immunity. 2018 Oct 16;49(4):695-708.e4
pubmed: 30291027
J Immunother Cancer. 2019 Feb 18;7(1):49
pubmed: 30777131
Blood. 1999 Mar 1;93(5):1634-42
pubmed: 10029592
Cancers (Basel). 2011 Dec 28;4(1):1-10
pubmed: 24213222
Lab Invest. 2023 May;103(5):100063
pubmed: 36801637
Nat Commun. 2019 Sep 13;10(1):4186
pubmed: 31519915
Cancer Res. 2012 Jul 15;72(14):3570-81
pubmed: 22581824
Genome Med. 2019 May 28;11(1):36
pubmed: 31138334
Cell Rep. 2021 Aug 24;36(8):109591
pubmed: 34433030
Science. 1990 Aug 24;249(4971):921-3
pubmed: 2118273
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
Nat Rev Clin Oncol. 2022 Apr;19(4):254-267
pubmed: 35082367
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33452206
Curr Opin Immunol. 2008 Apr;20(2):158-61
pubmed: 18456486
Cancer Discov. 2022 Oct 5;12(10):2280-2307
pubmed: 35929803
J Transl Med. 2018 Feb 15;16(1):30
pubmed: 29448960
Trends Cancer. 2016 Dec;2(12):747-757
pubmed: 28626801
JAAD Case Rep. 2016 Dec 03;2(6):439-441
pubmed: 27981212
J Immunother Cancer. 2016 Jul 19;4:40
pubmed: 27437104
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35304405
J Immunol. 2012 Nov 1;189(9):4674-83
pubmed: 23028051
Arthritis Res Ther. 2017 Jan 19;19(1):8
pubmed: 28103916
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9296-301
pubmed: 9256476
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Hum Gene Ther. 2002 May 1;13(7):815-27
pubmed: 11975848
J Immunol. 2013 Aug 1;191(3):1240-9
pubmed: 23804710
Pigment Cell Melanoma Res. 2012 Jul;25(4):493-505
pubmed: 22498258
Nature. 2021 Mar;591(7850):464-470
pubmed: 33536615
Immunity. 2011 Apr 22;34(4):566-78
pubmed: 21511185
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Signal Transduct Target Ther. 2023 May 22;8(1):207
pubmed: 37211559
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Nat Med. 2022 Dec;28(12):2592-2600
pubmed: 36526722
Cell Mol Immunol. 2017 Aug;14(8):662-674
pubmed: 28626234
Mol Immunol. 2019 May;109:20-26
pubmed: 30851633
Cancer Res. 2022 Jan 15;82(2):264-277
pubmed: 34810198
J Immunother Cancer. 2022 May;10(5):
pubmed: 35640928
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33688021
Nat Med. 2020 Dec;26(12):1845-1851
pubmed: 33046869
Br J Cancer. 2023 Jun;128(12):2175-2185
pubmed: 37016103
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251
pubmed: 31611368
Cancer Res. 2014 Jul 1;74(13):3454-65
pubmed: 24786787
Nat Rev Immunol. 2020 Apr;20(4):229-238
pubmed: 31836872
Int Immunol. 2013 Feb;25(2):129-37
pubmed: 23087177
Cancer Res. 2018 Sep 1;78(17):5011-5022
pubmed: 29967259
Front Immunol. 2018 Nov 20;9:2660
pubmed: 30515157
Cancer Immunol Immunother. 2011 Dec;60(12):1729-38
pubmed: 21779876
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Annu Rev Cell Dev Biol. 2020 Oct 6;36:551-574
pubmed: 33021823
Nat Immunol. 2016 Oct;17(10):1197-1205
pubmed: 27573866
Cancer Res. 2006 Aug 1;66(15):7741-7
pubmed: 16885377
Int J Cancer. 2021 Jul 15;149(2):403-408
pubmed: 33709428
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
Nat Immunol. 2008 Nov;9(11):1225-35
pubmed: 18820683
Eur Urol. 2021 Jun;79(6):793-795
pubmed: 33773871
J Clin Invest. 2013 Apr;123(4):1457-74
pubmed: 23454746
Cancer Cell. 2010 Feb 17;17(2):121-34
pubmed: 20138013
Exp Hematol Oncol. 2022 Apr 23;11(1):24
pubmed: 35461288
J Immunol. 2022 May 15;208(10):2425-2435
pubmed: 35437281
Cancer Cell. 2021 Oct 11;39(10):1293-1296
pubmed: 34597591
Pharmacol Ther. 2021 Mar;219:107709
pubmed: 33091428
Clin Cancer Res. 2011 Aug 1;17(15):4987-95
pubmed: 21690573
Nat Rev Clin Oncol. 2021 Apr;18(4):199-214
pubmed: 33437048
Nat Cancer. 2022 Sep;3(9):1123-1136
pubmed: 36138134
Science. 2011 Mar 4;331(6021):1203-7
pubmed: 21310965
Gut. 2023 Feb;72(2):325-337
pubmed: 35705369
Elife. 2018 Mar 09;7:
pubmed: 29521626
Ann Oncol. 2018 Jan 1;29(1):162-169
pubmed: 29077781
Oncoimmunology. 2017 Jun 8;6(9):e1326442
pubmed: 28932632
Eur J Immunol. 1994 Dec;24(12):3237-40
pubmed: 7805753
Immunology. 2003 Nov;110(3):296-303
pubmed: 14632656
J Immunother Cancer. 2022 Nov;10(11):
pubmed: 37011953
Cancer Cell. 2022 Mar 14;40(3):289-300.e4
pubmed: 35216676
PLoS One. 2012;7(1):e30139
pubmed: 22291907
J Immunother Cancer. 2023 Mar;11(3):
pubmed: 36882226
Breast Cancer Res Treat. 2012 Apr;132(2):545-53
pubmed: 21671016
Front Pharmacol. 2017 Feb 08;8:49
pubmed: 28228726
Immunity. 2023 Oct 10;56(10):2254-2269
pubmed: 37699391
Nat Commun. 2023 Jun 8;14(1):3378
pubmed: 37291228
J Exp Med. 2021 Aug 2;218(8):
pubmed: 34106207
Cancer Res. 2012 Aug 15;72(16):3997-4007
pubmed: 22850419
Breast Cancer Res Treat. 2014 Jan;143(2):265-76
pubmed: 24337540
Cancer Cell. 2019 Jun 10;35(6):901-915.e4
pubmed: 31185213
Nat Med. 2019 Mar;25(3):487-495
pubmed: 30842675
Cancer Res. 2015 Dec 1;75(23):5008-13
pubmed: 26573795
Trends Immunol. 2021 Dec;42(12):1128-1142
pubmed: 34750058
Cancer Res. 2006 Oct 1;66(19):9576-82
pubmed: 17018614
Cancers (Basel). 2021 Jan 21;13(3):
pubmed: 33494389
N Engl J Med. 1987 Apr 9;316(15):889-97
pubmed: 3493432
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Arthritis Rheum. 2011 Dec;63(12):3918-30
pubmed: 22127708
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35444058
N Engl J Med. 1998 Apr 30;338(18):1272-8
pubmed: 9562581
Immunity. 2022 Mar 8;55(3):527-541.e5
pubmed: 35231421
Nat Commun. 2021 Mar 9;12(1):1540
pubmed: 33750785
Br J Urol. 1998 Oct;82(4):487-93
pubmed: 9806175
Cancer Cell. 2018 Nov 12;34(5):775-791.e3
pubmed: 30423297
Sci Rep. 2019 Oct 18;9(1):14963
pubmed: 31628349
Nat Rev Cancer. 2019 Dec;19(12):698-715
pubmed: 31666715
Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8
pubmed: 34653365
Oncoimmunology. 2015 Jun 3;4(11):e1032492
pubmed: 26451312
Trends Immunol. 2015 Feb;36(2):92-101
pubmed: 25616716
Clin Immunol. 2007 Aug;124(2):182-9
pubmed: 17556024
Nat Rev Cancer. 2021 Aug;21(8):481-499
pubmed: 34083781
Immunol Rev. 2021 Jan;299(1):74-92
pubmed: 33368346
Nat Med. 2020 Nov;26(11):1733-1741
pubmed: 32895571
Clin Cancer Res. 2021 Jan 15;27(2):492-503
pubmed: 32887723
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Cell. 2021 Dec 9;184(25):6101-6118.e13
pubmed: 34852236
J Clin Invest. 2018 Feb 1;128(2):715-720
pubmed: 29309048
Nat Commun. 2015 Jan 22;6:5997
pubmed: 25609381
Cancer Cell. 2022 May 9;40(5):509-523.e6
pubmed: 35537412
J Immunol. 2010 Apr 1;184(7):4006-16
pubmed: 20194720
Oncoimmunology. 2018 Sep 19;8(1):e1513440
pubmed: 30546953
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
Nat Cancer. 2021 Aug;2(8):794-802
pubmed: 35118423
Cancer Immunol Immunother. 2001 Oct;50(8):391-6
pubmed: 11726133
Eur Respir J. 2007 Oct;30(4):627-32
pubmed: 17537769
Cell. 2022 Mar 31;185(7):1208-1222.e21
pubmed: 35305314
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457
pubmed: 35365796
Gene Ther. 1999 Oct;6(10):1705-12
pubmed: 10516719
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Nature. 2023 Jul;619(7969):348-356
pubmed: 37344597
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Nat Immunol. 2002 Oct;3(10):944-50
pubmed: 12244307
Nature. 2015 May 7;521(7550):99-104
pubmed: 25924063
Commun Med (Lond). 2022 May 11;2:48
pubmed: 35603273
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
J Transl Med. 2015 May 20;13:168
pubmed: 25990390
J Exp Med. 2017 Nov 6;214(11):3207-3217
pubmed: 28899868
Front Immunol. 2021 Nov 24;12:759217
pubmed: 34899709
Nat Commun. 2022 Jun 3;13(1):3121
pubmed: 35660734
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
JCI Insight. 2020 May 21;5(10):
pubmed: 32434989
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7
pubmed: 21670304
Cell Rep. 2015 Nov 10;13(6):1118-1124
pubmed: 26527008
Front Immunol. 2020 Oct 21;11:535784
pubmed: 33193306
Nat Immunol. 2009 Dec;10(12):1292-9
pubmed: 19855380
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Immunotherapy. 2009 Mar;1(2):281-8
pubmed: 20046960